Methods: A consecutive 117 patients (mean age, 71 6 8 years; 95 men) undergoing IAAA repair between 2004 and 2016 were included. Primary outcomes were all-cause mortality and AAA-related mortality. Freedom from reintervention, presence of hydronephrosis (HF) caused by perianeurysmal fibrosis, and renal insufficiency (defined as absolute serum creatinine value >2 mg/dL or an increased value >0.5 mg/dL vs the baseline one) before and after repair at the last follow-up were considered secondary end points. EVAR was performed according to the instructions for use of each device.
IP035.
Objective: Endovascular repair of complex abdominal aortic aneurysms (AAAs) has become increasingly common, but reports have been mostly limited to single-center and single-device studies.
Methods: We studied all endovascular repairs of complex AAA (zone 6 or caudal) from 2012 to 2017 in the Vascular Quality Initiative. This included all fenestrated, branched, and snorkel/chimney repairs composed of off-the-shelf, custom-manufactured, and physician-modified devices.
Results: There were 1663 complex endovascular repairs; 1534 (92%) were performed electively, 83 (5%) were symptomatic, and 45 (3%) were ruptured. The average age was 74 (6 8) years; 22% were female, and 87% were white. There were 604 off-the-shelf fenestrated devices, 673 custom-manufactured grafts, 189 physician-modified devices, and 197 chimney/snorkels. There were 4958 renal-visceral vessels intervened on: 391 (24%) repairs involving two vessels, 646 (39%) three vessels, and 557 (33%) four vessels, with a median of three (interquartile range, two to four). The number of centers contributing complex repairs expanded from 2 centers in 2 regions in 2012 to 81 centers from 17 regions in 2017. The number of repairs increased steadily from 5 in 2012 to 525 in 2016. Eleven percent of patients had prior AAA repairs. The rate of perioperative death was 3.5% for elective cases, 6% for symptomatic, and 22% for ruptures, with no significant change over time and no difference based on repair type. The overall perioperative complication rate was 29%. By RIFLE (Risk, Injury, Failure, Loss of kidney function, and End-stage) criteria, 309 patients (19%) experienced acute kidney injury: risk, 98 (6%); injury, 76 (5%); failure, 85 (5%); loss of function (temporary dialysis), 21 (1.3%); endstage renal disease, 29 (2%). Twelve patients (0.7%) underwent open conversion during the index hospitalization. There were 46 (3%) patients with mesenteric ischemia, 19 of whom (1%) underwent bowel resections. Sixteen patients (1%) experienced strokes, 4 patients (0.2%) suffered transient ischemic attacks, and 60 patients (4%) had myocardial infarctions. There were 62 patients reintubated after the initial procedure (4%), and 109 patients (7%) had access site complications. During the index hospitalization, 75 patients (5%) underwent reinterventions related to their aneurysm, and 10 (1%) underwent unrelated operations. The 1-, 2-, and 3-year mortality rates were 91%, 89%, and 88%, respectively, with no significant difference by device type (P ¼ .30).
Conclusions: Complex endovascular repair is becoming increasingly common, both in the number of operations and in the number of centers and regions in which they occur. Rates of perioperative morbidity and mortality as well as 2-year survival are acceptable, but further study is needed to establish the durability of these novel technologies.
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Outcomes of the First 100 Consecutive Zenith Fenestrated Endovascular Grafts at a Single Center
Methods: A prospectively maintained database of all aortic aneurysm repairs was queried for all fenestrated endovascular aneurysm repairs (FEVARs) performed since July 2013. Demographic data were obtained in addition to aortic anatomic characteristics, periprocedural details (radiation dose available after June 2015), and postoperative outcomes. Statistical analysis was performed with the SAS software package (SAS Institute, Cary, NC).
Results: There were 100 FEVARs performed from July 2013 to June 2017 (80% male; mean age, 73 6 8.1 years). Two surgeons performed 92% of cases. All cases were elective; 91 were performed for aneurysm disease (28% juxtarenal, 63% pararenal), and 9 were performed for type I endoleaks. There was a 98% aneurysm exclusion rate with 264 vessels cannulated through 272 fenestrations (97% technical success). Graft
